Eric R. Olson
Net Worth
Last updated:
What is Eric R. Olson net worth?
The estimated net worth of Dr. Eric R. Olson is at least $5,622,296 as of 17 Jul 2023. He owns shares worth $37 as insider, has earned $50,899 from insider trading and has received compensation worth at least $5,571,360 in Syros Pharmaceuticals, Inc..
What is the salary of Eric R. Olson?
Dr. Eric R. Olson salary is $696,420 per year as Chief Scientific Officer in Syros Pharmaceuticals, Inc..
How old is Eric R. Olson?
Dr. Eric R. Olson is 67 years old, born in 1958.
What stocks does Eric R. Olson currently own?
As insider, Dr. Eric R. Olson owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. (SYRS) | Chief Scientific Officer | 6,661 | $0.01 | $37 |
What does Syros Pharmaceuticals, Inc. do?
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Eric R. Olson insider trading
Syros Pharmaceuticals, Inc.
Dr. Eric R. Olson has made 10 insider trades between 2017-2023, according to the Form 4 filled with the SEC. Most recently he sold 689 units of SYRS stock worth $2,412 on 17 Jul 2023.
The largest trade he's ever made was exercising 12,500 units of SYRS stock on 25 Jul 2017. As of 17 Jul 2023 he still owns at least 6,661 units of SYRS stock.
Syros Pharmaceuticals key executives
Syros Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. David A. Roth (62) Chief Medical Officer
- Dr. Eric R. Olson (67) Chief Scientific Officer
- Dr. Nancy A. Simonian M.D. (64) Pres, Chief Executive Officer & Director
- Dr. Richard A. Young Ph.D. (71) Scientific Founder, Member of Scientific Advisory Board & Director